

FGFR4 (Phospho-Tyr642) Antibody

Catalog No: #11836

Package Size: #11836-1 50ul #11836-2 100ul

Orders: order@signalwayantibody.comSupport: tech@signalwayantibody.com


Description

Product Name	FGFR4 (Phospho-Tyr642) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB,ELISA
Species Reactivity	Human, Mouse, Rat
Specificity	The antibody detects endogenous levels of FGFR4 only when phosphorylated at tyrosine 642.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 642(I-D-Y(p)-Y-K) derived from Human FGFR4 .
Conjugates	Unconjugated
Target Name	FGFR4
Modification	Phospho
Other Names	FGFR-4; CD_antigen=CD334; Fibroblast growth factor receptor 4; EC=2.7.10.1;
Accession No.	Swiss-Prot#: P22455; NCBI Gene#: 2264; NCBI Protein#: NP_002002.3.
SDS-PAGE MW	90kd
Concentration	1.0mg/ml
Formulation	Rabbit IgG in phosphate buffered saline (without Mg ²⁺ and Ca ²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C/1 year


Application Details

Western blotting: 1:500~1:1000

Images



Western blot analysis of extracts from JK cells (Lane 2), using FGFR4 (Phospho-Tyr642) Antibody #11836. The lane on the left is treated with antigen-specific peptide.



Western blot analysis of extracts from Jurkat, using Phospho-FGFR4 (Tyr642) Antibody. Lane1 was treated with phospho-blocking peptide, Lane2 was treated with non-phospho-blocking peptide.

Background

Receptor for acidic fibroblast growth factor. Does not bind to basic fibroblast growth factor. Binds FGF19.

Partanen J.M., EMBO J. 10:1347-1354(1991) [PubMed: 1709094].

Ron D., J. Biol. Chem. 268:5388-5394(1993) [PubMed: 7680645].

Takaishi S., Biochem. Biophys. Res. Commun. 267:658-662(2000) [PubMed: 10631118].

Published Papers

el at., Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. In Oncol Rep on 2015 Nov by Lingling Hu , Lanxiang Cong. PMID:26323668, , (2015)

[PMID:26323668](#)

el at., Loss of E-cadherin Activates a Targetable IGF1R Pathway in Invasive Lobular Breast Carcinoma. In Mol Cancer Res on 2022 Sep 2 by Ashuvinee Elangovan, Jagmohan Hooda, et al.. PMID:35665642, , (2022)

[PMID:35665642](#)

el at., Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. In Mol Cancer Res on 2022 Sep 2 by Ashuvinee Elangovan, Jagmohan Hooda, et al.. PMID:35665642, , (2022)

[PMID:35665642](#)

el at., Estrogen regulation and functional role of FGFR4 in estrogen receptor positive breast cancer. In bioRxiv [Preprint] on 2024 Mar 20 by Kai Ding, Lyuqin Chen, et al.. PMID:38562741, , (2024)

[PMID:38562741](#)

Kai Ding;Lyuqin Chen;Kevin M Levine;Matthew J Sikora;Nilgun Tasdemir;David Dabbs;Rachel Jankowitz;Rachel Hazan;Osama Shah;Jenny Atkinson;Adrian V Lee;Steffi Oesterreich el at., FGFR4 in endocrine resistance: overexpression and estrogen regulation without direct causative role., , (2025)

[PMID:40097769](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.